<DOC>
	<DOCNO>NCT01683422</DOCNO>
	<brief_summary>The current trial provide important data recurrence rate pattern failure use state art target agent , chemotherapy proton beam technology patient Locally Advanced Pancreatic Cancer ( LAPC ) . A median survival 10 month great would consider evidence regimen potentially worthy study new treatment paradigm one arm future phase III trial .</brief_summary>
	<brief_title>Chemotherapy Plus Proton-chemotherapy Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically confirm unresectable nonmetastatic adenocarcinoma pancreas AJCC stage IIII unresectable borderline unresectable disease define NCCN guideline Radiological resectability define follow criterion abdominal imaging : 1 . No evidence tumor extension celiac axis , hepatic artery superior mesenteric artery . 2 . No evidence tumor encasement occlusion superior mesenteric vein ( SMV ) SMV/portal vein confluence 3 . No evidence visceral peritoneal metastasis Borderline Unresectable case would define meet criterion section also show evidence distant metastatic intraperitoneal disease . Eastern Cooperative Oncology Group performance status ≤ 2 Age &gt; 18 year Adequate hematologic reserve , hepatic reserve renal function WBC &gt; 2,000 cells/mm3 ANC &gt; 1,500 cells/mm3 Platelets &gt; 100,000 cells/mm3 Serum bilirubin ≤ 2.5 mg/dL Serum creatinine ≤ 2 x upper limit normal ( ULN ) , creatinine clearance ( Ccr ) ≥ 30ml/min ALT &lt; 3 time ULN AST &lt; 3 time ULN Albumin &gt; 3.2 g/dl Patient must sign studyspecific inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>